Compare Fastly Inc (FSLY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Twist Bioscience Corp — how do they compare? Fastly Inc trades at $29.51 (market cap $4.03B), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 2.5× Fastly Inc's market cap, and Fastly Inc is more actively traded (5,516,495 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Twist Bioscience Corp for 27 Days on average.
| FSLY | TWST | |
|---|---|---|
Market Cap | $4.03B | $10.08B |
Volume | 5,516,495 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $33.50 | $205.00 |
52-Week Low | $7.86 | $25.45 |
Typical Hold Time | 26 Days | 27 Days |
Enterprise Value | $4.09B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $29.3, up 15.9% on the day, with a neutral technical signal and bullish moving averages. The company reported three consecutive quarterly EPS beats, with Q3 2026 expected at $0.1186. Revenue growth is strong, reaching $624M in 2025, but net losses persist, though margins are improving. Recent news highlights AI-driven demand and insider selling by the CTO, creating mixed sentiment.
The outlook is cautiously optimistic, with revenue projected to hit $687M in 2026 and a path to profitability. Risks include sustained losses, competitive pressure, and high valuation multiples. Analyst consensus is mixed, with a $28.25 price target slightly below current levels, suggesting limited near-term upside amid growth execution risks.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
